• 1
    Cancer care during the last phase of life. J Clin Oncol. 1998; 16: 19861996.
  • 2
    Morrison RS,Siu AL,Leipzig RM,Cassel CK,Meier DE. The hard task of improving the quality of care at the end of life. Arch Intern Med. 2000; 160: 743747.
  • 3
    Patrick DL,Curtis JR,Engelberg RA,Nielsen E,McCown E. Measuring and improving the quality of dying and death. Ann Intern Med. 2003; 139(5 Pt 2): 410415.
  • 4
    Singer PA,Martin DK,Kelner M. Quality end-of-life care: patients' perspectives. JAMA. 1999; 281: 163168.
  • 5
    Steinhauser KE,Christakis NA,Clipp EC, et al. Preparing for the end of life: preferences of patients, families, physicians, and other care providers. J Pain Symptom Manage. 2001; 22: 727737.
  • 6
    Steinhauser KE,Christakis NA,Clipp EC,McNeilly M,McIntyre L,Tulsky JA. Factors considered important at the end of life by patients, family, physicians, and other care providers. JAMA. 2000; 284: 24762482.
  • 7
    Steinhauser KE,Clipp EC,McNeilly M,Christakis NA,McIntyre LM,Tulsky JA. In search of a good death: observations of patients, families, and providers. Ann Intern Med. 2000; 132: 825832.
  • 8
    Lorenz KA,Lynn J,Dy S, et al. Quality measures for symptoms and advance care planning in cancer: a systematic review. J Clin Oncol. 2006; 24: 49334938.
  • 9
    Voogt E,van der Heide A,Rietjens JA, et al. Attitudes of patients with incurable cancer toward medical treatment in the last phase of life. J Clin Oncol. 2005; 23: 20122019.
  • 10
    Earle CC,Neville BA,Landrum MB,Ayanian JZ,Block SD,Weeks JC. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol. 2004; 22: 315321.
  • 11
    Earle CC,Park ER,Lai B,Weeks JC,Ayanian JZ,Block S. Identifying potential indicators of the quality of end-of-life cancer care from administrative data. J Clin Oncol. 2003; 21: 11331138.
  • 12
    Bruera E,Russell N,Sweeney C,Fisch M,Palmer JL. Place of death and its predictors for local patients registered at a comprehensive cancer center. J Clin Oncol. 2002; 20: 21272133.
  • 13
    Emanuel EJ,Young-Xu Y,Levinsky NG,Gazelle G,Saynina O,Ash AS. Chemotherapy use among Medicare beneficiaries at the end of life. Ann Intern Med. 2003; 138: 639643.
  • 14
    Huang J,Boyd C,Tyldesley S,Zhang-Salomons J,Groome PA,Mackillop WJ. Time spent in hospital in the last six months of life in patients who died of cancer in Ontario. J Clin Oncol. 2002; 20: 15841592.
  • 15
    Murillo JRJr,Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist. 2006; 11: 10951099.
  • 16
    Bach PB,Schrag D,Begg CB. Resurrecting treatment histories of dead patients: a study design that should be laid to rest. JAMA. 2004; 292: 27652770.
  • 17
    Bradley EH,Prigerson H,Carlson MD,Cherlin E,Johnson-Hurzeler R,Kasl SV. Depression among surviving caregivers: does length of hospice enrollment matter? Am J Psychiatry. 2004; 161: 22572262.
  • 18
    Dawson NJ. Need satisfaction in terminal care settings. Soc Sci Med. 1991; 32: 8387.
  • 19
    Kane RL,Berstein L,Wales J,Rothenberg R. Hospice effectiveness in controlling pain. JAMA. 1985; 253: 26832686.
  • 20
    Kane RL,Wales J,Bernstein L,Leibowitz A,Kaplan S. A randomised controlled trial of hospice care. Lancet. 1984; 1: 890894.
  • 21
    Kris AE,Cherlin EJ,Prigerson H, et al. Length of hospice enrollment and subsequent depression in family caregivers: 13-month follow-up study. Am J Geriatr Psychiatry. 2006; 14: 264269.
  • 22
    Wallston KA,Burger C,Smith RA,Baugher RJ. Comparing the quality of death for hospice and non-hospice cancer patients. Med Care. 1988; 26: 177182.
  • 23
    Temel JS,Jackson VA,Billings JA, et al. Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients. J Clin Oncol. 2007; 25: 23772382.
  • 24
    Cella DF,Bonomi AE,Lloyd SR,Tulsky DS,Kaplan E,Bonomi P. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer. 1995; 12: 199220.
  • 25
    Zigmond AS,Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67: 361370.
  • 26
    Aragon-Ching JB,Cohn JB,Cohn A. Chemotherapy at the end of life. Proc Am Soc Clin Oncol. 2003; 22: 776.
  • 27
    Giorgi F,Bascioni R,Brugni M, et al. Chemotherapy use at the end of life: an analysis of the decision making process. J Clin Oncol. 2004; 22: 6081.
  • 28
    Nonsmall Cell Lung Cancer Cooperative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group [see comment]. BMJ. 1995; 311: 899909.
  • 29
    Fossella FV,DeVore R,Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000; 18: 23542362.
  • 30
    Fukuoka M,Yano S,Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003; 21: 22372246.
  • 31
    Hanna N,Shepherd FA,Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004; 22: 15891597.
  • 32
    Kris MG,Natale RB,Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. [see comment]. JAMA. 2003; 290: 21492158.
  • 33
    Shepherd FA,Dancey J,Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18: 20952103.
  • 34
    Shepherd FA,Rodrigues Pereira J,Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123132.
  • 35
    Jean-Yves D,Kim E,Hirsh V, et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pre-treated with platinum-based chemotherapy: a randomized open-label Phase III study (INTEREST). Presented at: 12th World Conference on Lung Cancer, 2007; Seoul, Korea.
  • 36
    Anderson H,Hopwood P,Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer—a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer. 2000; 83: 447453.
  • 37
    Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst. 1999; 91: 6672.
  • 38
    Hardy JR,Noble T,Smith IE. Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. Br J Cancer. 1989; 60: 764766.
  • 39
    Roszkowski K,Pluzanska A,Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000; 27: 145157.
  • 40
    Temel J. Complexities of quality of life analysis in non-small cell lung cancer. J Support Oncol. 2007; 5: 3031.
  • 41
    Brown J,Thorpe H,Napp V, et al. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol. 2005; 23: 74177427.
  • 42
    Miller SC,Kinzbrunner B,Pettit P,Williams JR. How does the timing of hospice referral influence hospice care in the last days of life? J Am Geriatr Soc. 2003; 51: 798806.
  • 43
    Rickerson E,Harrold J,Kapo J,Carroll JT,Casarett D. Timing of hospice referral and families' perceptions of services: are earlier hospice referrals better? J Am Geriatr Soc. 2005; 53: 819823.
  • 44
    Wright AA,Katz IT. Letting go of the rope—aggressive treatment, hospice care and open access. N Engl J Med. 2007; 357: 324327.
  • 45
    Weeks JC,Cook EF,O'Day SJ, et al. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA. 1998; 279: 17091714.
  • 46
    Rose JH,O'Toole EE,Dawson NV, et al. Perspectives, preferences, care practices, and outcomes among older and middle-aged patients with late-stage cancer. J Clin Oncol. 2004; 22: 49074917.